

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The mechanism of action of cemiplimab is best described by which of the following antibody types?**
  - a. BRAF blocker
  - b. LAG-3 blocker
  - c. PD-1 blocker**
  - d. PD-L1 blocker
  - e. TIM-3 blocker
- 2. Published results from the Phase II EMPOWER study report substantial antitumor activity with cemiplimab in which of the following populations of patients with cutaneous squamous cell carcinoma?**
  - a. Those with locally advanced disease
  - b. Those with metastatic disease
  - c. Both a and b**
  - d. Neither a nor b
- 3. Which of the following hedgehog inhibitors is approved for basal cell carcinoma?**
  - a. Sonidegib
  - b. Vismodegib
  - c. Glasdegib
  - d. All of the above
  - e. a and b only**
  - f. b and c only
- 4. Which of the following statements is true of immune-related adverse events (irAEs) in patients who receive immune checkpoint inhibitor therapy?**
  - a. irAEs primarily affect the immune and endocrine systems
  - b. irAEs primarily affect the circulatory and respiratory systems
  - c. irAEs primarily affect the digestive and urinary systems
  - d. irAEs can affect any organ system**
- 5. The Phase III C-POST trial is evaluating adjuvant \_\_\_\_\_ versus placebo after surgery and radiation therapy for patients with high-risk cutaneous squamous cell carcinoma.**
  - a. Atezolizumab
  - b. Cemiplimab**
  - c. Cetuximab
  - d. Pembrolizumab